Developing novel therapeutic strategies to target DNA damage response
Timothy Yap • 13 Apr 2022
Phase I study of the ATR inhibitor M1774 in patients with solid tumors
Timothy Yap • 10 Sep 2022
VT3989YAP, a YAP/TEAD inhibitor, in mesothelioma and NF2-mutant cancers
Timothy Yap • 16 Apr 2023
Breast cancer patients with germline BRCA mutations: can we preserve fertility?